Intellectual Disability

Intellectual Disability (ID), termed Intellectual Developmental Disorder in DSM-5-TR, is a neurodevelopmental disorder with onset during the developmental period. It involves deficits in both intellectual functioning and adaptive functioning across conceptual, social, and practical domains. DSM-5-TR deliberately de-emphasises IQ score cutoffs in favour of adaptive functioning as the primary severity determinant. References: DSM-5-TR, StatPearls (NCBI Bookshelf).

Intellectual Disability (ID), termed Intellectual Developmental Disorder in DSM-5-TR, is a neurodevelopmental disorder with onset during the developmental period. It involves deficits in both intellectual functioning and adaptive functioning across conceptual, social, and practical domains. DSM-5-TR deliberately de-emphasises IQ score cutoffs in favour of adaptive functioning as the primary severity determinant. The previous term "mental retardation" was replaced in DSM-5 (2013), following Rosa's Law (2010) in the US, which mandated substitution in federal legislation. ID is classified under Neurodevelopmental Disorders in DSM-5-TR and carries ICD-11 code 6A00. It is not a single disease but a heterogeneous group of conditions sharing the common feature of significantly below-average intellectual and adaptive capacities originating before adulthood. Approximately 85% of cases are mild. This information is for psychoeducation only.

Signs vary by severity level. Mild ID (IQ ~50-70, ~85% of cases): children typically show delayed speech and language development, difficulty with reading and arithmetic by school age, and limited abstract thinking. Social judgement is immature. Adults can live independently with some support, hold jobs, manage basic finances, and maintain relationships, though complex planning and problem-solving remain difficult. Moderate ID (IQ ~35-49, ~10%): language develops slowly; spoken communication is functional but simplified. Academic skills plateau around 2nd-grade level. Adults need moderate support for daily living — meal preparation, transportation, money management. Social interactions are simpler; friendships are maintained with support. Severe ID (IQ ~20-34, ~3-4%): very limited spoken language; communicates through basic words, signs, or gestures. Needs extensive daily supervision for self-care (dressing, bathing, toileting). Can learn simple routines with repetitive training. Profound ID (IQ <20, ~1-2%): minimal or no symbolic communication; reliant on others for all aspects of daily care. May have significant motor impairments. Often co-occurs with sensory deficits, epilepsy, and physical disabilities. Across all levels: developmental milestones (sitting, walking, first words) are delayed relative to age norms.

Genetic factors account for approximately 30-50% of identified cases: chromosomal abnormalities (Down syndrome — trisomy 21, the most common chromosomal cause, ~1 in 700 births), single-gene disorders (Fragile X syndrome — the most common inherited cause, affecting ~1 in 4,000 males; phenylketonuria (PKU); tuberous sclerosis; Rett syndrome), copy number variants, and de novo mutations. Prenatal factors: fetal alcohol spectrum disorder (FASD) — the most common preventable cause of ID; maternal infections (rubella, CMV, toxoplasmosis, Zika virus); teratogen exposure (valproate, isotretinoin, lead, methylmercury);

maternal malnutrition, untreated hypothyroidism, and uncontrolled diabetes. Perinatal factors: prematurity (especially <32 weeks), very low birth weight (<1500g), birth asphyxia, and neonatal hyperbilirubinemia. Postnatal factors: bacterial meningitis, viral encephalitis, traumatic brain injury, lead poisoning, severe malnutrition (protein-energy malnutrition, iodine deficiency), and severe psychosocial deprivation. In ~30-50% of cases, no specific cause is identified despite testing.

Genetic causes: Down syndrome (trisomy 21) accounts for ~15-20% of ID cases. Fragile X syndrome results from CGG trinucleotide repeat expansion (>200 repeats) in the FMR1 gene on Xq27.3, silencing FMRP production — FMRP regulates translation of hundreds of synaptic proteins, and its absence disrupts synaptogenesis. PKU results from phenylalanine hydroxylase deficiency (autosomal recessive), causing toxic phenylalanine accumulation that damages developing white matter — universally screened at birth; early dietary restriction prevents ID. Williams syndrome (7q11.23 microdeletion, ~28 genes including elastin) causes mild-moderate ID with a distinctive "cocktail party" personality and visuospatial deficits. Prader-Willi syndrome (paternal 15q11-13 deletion or maternal uniparental disomy) causes hypotonia, hyperphagia, and mild-moderate ID. Angelman syndrome (maternal 15q11-13 deletion) causes severe ID with absent speech, seizures, and a happy demeanour. Environmental causes: prenatal alcohol exposure disrupts neuronal migration and cortical organisation. Birth asphyxia causes hippocampal and basal ganglia injury. Childhood meningitis damages cortex through inflammation and ischaemia. Iodine deficiency during pregnancy impairs fetal thyroid function and brain development — the leading preventable cause of ID worldwide.

Worldwide prevalence: approximately 1-3% of the population. A meta-analysis of 52 studies estimated pooled prevalence at 10.37 per 1,000 population. Mild ID accounts for ~85% of cases, moderate ~10%, severe ~3-4%, and profound ~1-2%. Male-to-female ratio: approximately 1.5:1, partly due to X-linked causes (Fragile X, Lesch-Nyhan, Hunter syndrome). Prevalence is higher in low- and middle-income countries due to limited prenatal care, nutrition deficiencies, infectious disease burden, and consanguinity. In the US, approximately 6.5 million people live with ID. Down syndrome occurs in ~1 in 700 live births. Co-occurring conditions are extremely common: ADHD (20-40%), autism spectrum disorder (10-30%), epilepsy (22-25%, rising to ~50% in severe/profound ID), mood and anxiety disorders at 3-4 times the rate of the general population, and challenging behaviours (aggression, self-injury, stereotypies) in 10-20%.

The pathophysiology varies with aetiology. Down syndrome: extra chromosome 21 leads to overexpression of genes including APP (amyloid precursor protein), DYRK1A (a kinase involved in neuronal development), and SOD1 (superoxide dismutase). Overexpression of APP causes early-onset amyloid deposition — virtually all individuals with Down syndrome develop Alzheimer's neuropathology by age 40. DYRK1A overexpression impairs neurogenesis in the hippocampus. Reduced dendritic branching and synaptic density are seen in cortical neurons. Fragile X: absence of FMRP causes excessive mGluR5 (metabotropic glutamate receptor 5)

signalling, leading to exaggerated long-term depression (LTD) at synapses — the "mGluR theory of Fragile X." Dendritic spines are long, thin, and immature-looking, reflecting impaired synaptic pruning. PKU: accumulated phenylalanine is neurotoxic to oligodendrocytes, disrupting myelination; it also inhibits large neutral amino acid transport across the blood-brain barrier, reducing brain tyrosine and tryptophan (precursors for dopamine and serotonin). Fetal alcohol: alcohol disrupts neuronal migration, causes apoptosis in developing cortex and cerebellum, and impairs midline development (corpus callosum agenesis in severe cases). General findings across aetiologies include reduced brain volume, abnormal cortical gyration, decreased synaptic density, and altered neurotransmitter function.

Assessment requires: (1) Detailed developmental history — age of sitting, walking, first words, sentence formation, toilet training, compared with normative milestones. Obtain from parent/caregiver and medical records. (2) Family history — consanguinity, prior children with ID, family history of genetic conditions, miscarriages. (3) Pregnancy and birth history — maternal substance use, infections, teratogen exposure, gestational age, birth complications, neonatal ICU admission, Apgar scores. (4) Physical examination for dysmorphic features: Down syndrome (epicanthal folds, flat nasal bridge, single transverse palmar crease, Brushfield spots on iris, hypotonia); Fragile X (long face, large ears, macro-orchidism post-puberty, hypermobile joints); Fetal alcohol syndrome (short palpebral fissures, smooth philtrum, thin upper lip, microcephaly); Williams syndrome (elfin facies, periorbital fullness, wide mouth, stellate iris pattern); Prader-Willi (obesity, small hands/feet, hypogonadism); tuberous sclerosis (hypopigmented macules — ash-leaf spots, facial angiofibromas, shagreen patches). (5) Neurological exam: tone, reflexes, gait, coordination, cranial nerves, head circumference (microcephaly or macrocephaly). (6) Sensory screening: vision and hearing testing — deficits are common and compound developmental delays.

DSM-5-TR requires all three criteria: (A) Deficits in intellectual functions — reasoning, problem-solving, planning, abstract thinking, judgement, academic learning, and learning from experience — confirmed by clinical evaluation AND standardised intelligence testing. IQ approximately 2 standard deviations below mean (~65-75, accounting for measurement error of ±5 points).

However, DSM-5-TR specifies that severity is determined by adaptive functioning, not IQ score alone. (B) Deficits in adaptive functioning that result in failure to meet developmental and sociocultural standards for personal independence and social responsibility. Without ongoing support, adaptive deficits limit functioning in one or more activities of daily life (communication, social participation, independent living). (C) Onset of intellectual and adaptive deficits during the developmental period (before age 18). Severity levels (defined by adaptive functioning, not IQ): Mild: IQ ~50-70. Can live independently with support. Competitive employment feasible. Moderate: IQ ~35-49. Can perform self-care with moderate support. Sheltered or supported employment. Severe: IQ ~20-34. Requires extensive support. Limited self-care skills. Profound: IQ <20. Full-time custodial care needed. ICD-11 code: 6A00 (Disorders of Intellectual Development), with severity subcodes 6A00.0 (mild) through 6A00.4 (profound).

Intelligence testing: Wechsler Intelligence Scales (WISC-V for children, WAIS-IV for adults) — provide full-scale IQ plus index scores (verbal comprehension, visual spatial, fluid reasoning, working memory, processing speed). Stanford-Binet Intelligence Scales (5th ed.) — useful for lower-functioning individuals. For non-verbal or severely impaired individuals: Leiter International Performance Scale (Leiter-3), Bayley Scales of Infant and Toddler Development (Bayley-4). Adaptive functioning assessment: Vineland Adaptive Behavior Scales (VABS-3) — measures communication, daily living skills, socialisation, and motor skills via caregiver interview. Adaptive Behavior Assessment System (ABAS-3). Genetic testing: chromosomal microarray analysis (CMA) is recommended as first-tier genetic testing — detects clinically significant copy number variants in ~15-20% of cases. Fragile X DNA testing (FMR1 CGG repeat analysis). Whole-exome sequencing is increasingly used when CMA and targeted tests are negative — diagnostic yield ~30-40% in unexplained ID. Metabolic screening: newborn screening panel (PKU, hypothyroidism, galactosemia, etc.); additional metabolic workup if clinical suspicion. Neuroimaging: MRI of the brain — recommended when aetiology is unknown; abnormalities found in ~30-40% of cases (cortical malformations, white matter abnormalities, cerebellar hypoplasia). EEG if seizures are suspected.

Global developmental delay (GDD): used in children <5 years when formal IQ testing is unreliable; children with GDD may or may not go on to meet ID criteria. Autism spectrum disorder (ASD): ~30% of individuals with ASD also have co-occurring ID; social communication deficits and restricted behaviours distinguish ASD. Specific learning disorders (dyslexia, dyscalculia): normal IQ with isolated academic skill deficits. Language disorders: delayed language with normal non-verbal cognition. ADHD: inattention and poor academic performance can mimic mild ID; IQ testing clarifies. Hearing and vision impairment: undetected sensory deficits can look like intellectual deficits, especially in young children. Childhood-onset neurodegenerative conditions (Rett syndrome, neuronal ceroid lipofuscinosis): progressive loss of skills rather than static deficits, though the distinction blurs in advanced stages. Reactive attachment disorder: severe

psychosocial deprivation causes developmental delays that may partially resolve with improved environment (unlike ID, which involves permanent cognitive limitations). Borderline intellectual functioning (IQ 71-84): does not meet criteria for ID but may require support.

Treatment and management of Intellectual Disability (ID) focuses on maximising adaptive functioning, supporting development, and addressing co-occurring conditions. Early Intervention: Early identification and intervention services (birth to age 3) are critical and include developmental therapies (speech-language, occupational, physical therapy), special education services, and family support. In the US, the Individuals with Disabilities Education Act (IDEA) Part C mandates early intervention services; Part B provides free appropriate public education through age 21. Educational and Vocational Support: Individualised Education Programs (IEPs) with appropriate accommodations and supports, social skills training, vocational training, and supported employment programmes help maximise independence and quality of life. Inclusion in general education settings with support (mainstreaming) is preferred when appropriate. Behavioural Interventions: Applied Behaviour Analysis (ABA) and positive behaviour support address challenging behaviours. Functional behavioural assessment identifies the purpose of problem behaviours (attention-seeking, escape, sensory stimulation, tangible reinforcement) and guides intervention design. Skills training targets communication, self-care, social interaction, and community living skills. Pharmacotherapy: Medication is used to treat co-occurring psychiatric conditions (ADHD, anxiety, depression, psychosis, aggression) rather than ID itself. Atypical antipsychotics (risperidone, aripiprazole) — FDA-approved for irritability in ASD — may be used for severe aggression or self-injury. Stimulants (methylphenidate, amphetamines) address comorbid ADHD, though effect sizes are smaller than in the general ADHD population and side effects (irritability, tics) may be more pronounced. SSRIs (fluoxetine, sertraline) treat comorbid anxiety and depression. Anticonvulsants (valproate, levetiracetam, lamotrigine) for co-occurring epilepsy. Careful monitoring for side effects is essential, as individuals with ID may have difficulty reporting them. The principle "start low, go slow" applies — begin at lower doses and titrate gradually. Family and Caregiver Support: Respite care, parent training, support groups, financial planning (special needs trusts, ABLE accounts), and advocacy services are important. Transition planning for adolescents addresses adult services, guardianship, residential options, and ongoing support needs. Health Monitoring: Regular screening for associated medical conditions (epilepsy, sensory impairments, congenital heart defects in Down syndrome, atlantoaxial instability in Down syndrome, metabolic conditions), preventive healthcare, and age-appropriate health maintenance are essential. The Down syndrome health care guidelines recommend echocardiography, thyroid function testing, audiometry, and ophthalmologic evaluation at regular intervals.

Prognosis varies markedly by severity and aetiology. Mild ID: with appropriate education and support, most individuals achieve functional independence, hold jobs, form relationships, and live in the community. Life expectancy approaches that of the general population in the absence of significant medical comorbidity.

Moderate ID: most achieve some independence in self-care and sheltered/supported employment; lifelong support is typically needed for complex tasks. Severe/Profound ID: individuals require lifelong extensive or pervasive support; quality of life is strongly influenced by the quality of residential care and support services. Life expectancy is reduced, particularly with severe co-occurring medical conditions (epilepsy, congenital heart disease, aspiration risk). Down syndrome life expectancy has increased from ~25 years in 1983 to >60 years today, due to cardiac surgery advances and improved medical care. Early intervention (before age 3) produces measurable gains in IQ, adaptive behaviour, and educational achievement. Prognosis is worse when there is co-occurring epilepsy, severe motor impairment, absence of spoken language, or multiple medical complications.

Psychiatric: individuals with ID develop mental disorders at 3-4 times the rate of the general population, but these are often unrecognised ("diagnostic overshadowing" — behavioural changes are attributed to ID rather than investigated as a separate treatable condition). Depression, anxiety, psychosis, and PTSD all occur but may manifest atypically (behavioural changes, aggression, self-injury, regression rather than typical verbal complaints). Epilepsy: affects 22-25% overall and up to 50% in severe/profound ID; seizure control is often more difficult, requiring multiple anticonvulsants. Challenging behaviours: aggression, self-injurious behaviour (head-banging, self-biting), property destruction, and pica affect 10-20% and cause significant caregiver burden. Aspiration and feeding difficulties: common in severe/profound ID; recurrent aspiration pneumonia is a leading cause of death. Abuse and exploitation: individuals with ID face 4-10 times the rate of physical, sexual, and emotional abuse compared to the general population. Premature mortality: life expectancy is reduced by 10-20 years on average, driven by epilepsy, respiratory infections, congenital anomalies, and accidents. Obesity: elevated rates, particularly in Down syndrome and Prader-Willi syndrome.

Primary prevention targets known causes: universal newborn screening for PKU, hypothyroidism, and other inborn errors of metabolism allows early dietary or medical intervention that prevents ID. Folic acid supplementation (400 mcg daily) before conception reduces neural tube defect risk by ~70%. Rubella vaccination prevents congenital rubella syndrome. Avoidance of alcohol during pregnancy prevents FASD — there is no established safe level of alcohol in pregnancy. Prenatal care including infection screening, glucose management, and avoidance of teratogens reduces risk. Iodine supplementation in deficient populations prevents cretinism. Secondary prevention: early developmental screening (using tools like the ASQ-3, PEDS, and M-CHAT-R) at well-child visits enables early intervention. Genetic counselling for families with known genetic risk factors. Patient and family education: ID is a lifelong condition requiring ongoing support, but individuals with ID can learn, grow, and participate in community life. Person-centred planning respects autonomy and individual goals. Health literacy materials should be adapted to appropriate reading levels (Easy Read format). Advocacy for inclusion and against institutionalisation has been central to the disability rights movement.

Ancient societies had varied approaches: some treated individuals with ID with compassion, others abandoned or killed them. The term "idiot" (Greek "idiotes," meaning private person) was used in legal and medical contexts for centuries. In the 19th century, Edouard Seguin pioneered educational approaches, founding the first schools for ID in France and the US. The eugenics movement (1900s-1940s) led to mass institutionalisation, forced sterilisation, and, in Nazi Germany, the T4 euthanasia programme that murdered an estimated 70,000-200,000 people with ID and other disabilities. The IQ test (Binet-Simon, 1905; Stanford-Binet, 1916) standardised assessment but also enabled classification-based discrimination. Deinstitutionalisation began in the 1960s-70s, driven by exposés of institutional abuse (Willowbrook State School, 1972) and the normalisation principle. DSM-I (1952) used "mental deficiency." DSM-II (1968): "mental retardation." DSM-5 (2013): "Intellectual Disability (Intellectual Developmental Disorder)." Rosa's Law (US, 2010) replaced "mental retardation" with "intellectual disability" in federal legislation. The UN Convention on the Rights of Persons with Disabilities (2006) affirmed equal rights, legal capacity, and inclusion.

The disability rights movement has driven a shift from the medical model (disability as individual deficit) to the social model (disability as a product of barriers imposed by society). Person-first language ("person with intellectual disability") is preferred in the US; identity-first language ("disabled person") is preferred by some self-advocates and in UK tradition. Self-advocacy organisations (People First, Self Advocates Becoming Empowered) give voice to individuals with ID. Employment rates remain low: in the US, only ~20% of adults with ID hold competitive employment, despite evidence that supported employment benefits both individuals and employers. Sheltered workshops are declining in favour of community-integrated employment. Housing: group homes, supported living, and host families have largely replaced large institutions in high-income countries, though institutional care persists in many low-resource settings. Special Olympics, founded by Eunice Kennedy Shriver in 1968, serves over 5 million athletes with ID worldwide. Access to healthcare remains a disparity — many physicians report inadequate training in caring for adults with ID, leading to missed diagnoses, poorer preventive care, and worse health outcomes.

Active research areas: (1) Genetics — whole-exome and whole-genome sequencing are identifying new causative genes at a rapid pace; as of 2024, over 1,500 genes have been associated with ID. Gene therapy trials for specific conditions (Angelman syndrome, Fragile X) are in early phases. (2) The mGluR5 theory in Fragile X — clinical trials of mGluR5 antagonists (mavoglurant, basimglurant) produced disappointing results, but research continues into downstream targets. (3) Down syndrome cognitive enhancement — the DYRK1A inhibitor programme and GABAergic modulation trials aim to improve learning and memory. (4) Digital health — tablet-based cognitive rehabilitation programmes, AAC (augmentative and alternative communication) devices, and telehealth delivery of behavioural interventions. (5) Ageing and ID — adults with Down syndrome face near-universal Alzheimer's neuropathology; anti-amyloid therapies are being studied in this population. (6) Precision medicine — matching treatment to genetic aetiology (e.g., enzyme replacement therapy in lysosomal storage diseases, dietary treatment in PKU). (7) CRISPR-based approaches — preclinical gene editing for monogenic causes of ID.

APA. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.; DSM-5-TR). APA Publishing. Sadock BJ, Sadock VA, Ruiz P. (Eds.). (2024). Kaplan & Sadock's Comprehensive Textbook of Psychiatry (11th ed.). Wolters Kluwer. StatPearls [Internet]. Intellectual Disability. NCBI Bookshelf. StatPearls Publishing. AAIDD. (2021). Intellectual Disability: Definition, Diagnosis, Classification, and Systems of Supports (12th ed.). AAIDD. WHO. (2022). ICD-11 for Mortality and Morbidity Statistics. Geneva: World Health Organization.

StatPearls Intellectual Disability: https://www.ncbi.nlm.nih.gov/books/NBK547654/ AAIDD (American Association on Intellectual and Developmental Disabilities): https://www.aaidd.org NIMH: https://www.nimh.nih.gov National Down Syndrome Society: https://www.ndss.org FRAXA Research Foundation (Fragile X): https://www.fraxa.org WHO ICD-11 code 6A00: https://icd.who.int Special Olympics: https://www.specialolympics.org Crisis: 988 (US Suicide & Crisis Lifeline); Text HOME to 741741 (Crisis Text Line) Note: Educational only. Not a substitute for professional care.